查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球急性症候群檢測市場（2023-2033）：按疾病類型、目標、樣本類型、最終用戶和國家進行分析和預測
市場調查報告書
商品編碼
1318830

全球急性症候群檢測市場（2023-2033）：按疾病類型、目標、樣本類型、最終用戶和國家進行分析和預測

Acute Care Syndromic Testing Market - A Global and Regional Analysis: Focus on Disease Type, Target, Sample Type, End User and Country Analysis - Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 227 Pages | 商品交期: 1-5個工作天內

價格
主要市場統計資料
開始年份 2023年
預測年份 2033
開始年的市場規模 34.3 億美元（2023年）
市場規模預測 34.3 億美元（2023年）
年複合成長率%： 9.43%

急性症候群檢測市場規模預計將從2022年的 31.4 億美元成長到2033年的 84.4 億美元，預測期內年複合成長率為 9.43%。

症候群測試組是一種分子診斷測試，可以同時檢測多種病原體。這些病原體通常具有相似或重疊的臨床表現，可以更佳管理患者，並根據具體表現更容易診斷。

由於對傳染病早期檢測的需求不斷增加，全球急性症候群檢測市場經歷顯著成長。傳染病流行的增加和流行病爆發的增加在市場成長中發揮著重要作用。此外，全球氣溫上升以及世界各地區新傳染病的發現也影響市場成長。

按疾病類型分類，呼吸系統疾病細分市場領先，2022年佔有率為56.29%。由於病毒性呼吸道疾病和肺炎的巨大負擔，症候群診斷測試是區分病毒性和細菌性呼吸道病原體的一種良好快速的方法，應該由最佳化抗菌藥物使用的醫院和醫生實施。

按照目標，到2022年，細菌細分市場將佔據市場佔有率 41.65%。細菌是具有簡單細胞結構的微生物，其調節中心含有遺傳資訊，即單個環中包含的 DNA。細菌可引起多種類型的感染，影響人類和動物。這些感染可以影響人體的任何部位，包括皮膚、大腦、肺部和血液。隨著細菌的繁殖，感染也會繁殖和傳播。

按樣本類型分類，拭子細分市場將在2022年以 51.90%的佔有率領先。拭子越來越受歡迎的主要原因是它們是一種易於使用、非侵入性且廉價的採樣方法。

從最終用戶來看，到2022年，醫院行業將以42.53%的佔有率引領市場。醫院處於在常規醫療程序中採用症候群測試組的最前沿。醫院，特別是北美、歐洲和亞太地區的醫院，整合症候群測試組和化驗，以提供優質的患者護理。

從地區來看，由於現有公司數量較多，北美地區的佔有率最大，2022年將達到40.41%。批准的增加和協同效應也增強了其市場主導地位。另一方面，亞太地區，尤其是中國和印度等人口大國，也在增加症候群檢測面板的採用，其中亞太地區的成長率最高，年複合成長率為10.97%。

本報告研究了全球急性症候群檢測市場，提供市場定義和概述、電動汽車隔離和分析方法、監管和報銷環境、市場影響因素和市場機會分析、市場規模轉變和市場機會。預測、按細分市場/區域進行的詳細分析、競爭格局、主要企業概況等

目錄

第1章 市場

  • 產品定義
  • 涵蓋和排除標準
  • 市場範圍
  • 調查方法

第2章 市場概況

  • 概述
  • 急性期症候群檢測工作流程分析
  • 市場足跡和成長潛力
  • 未來

第3章 行業考察

  • 利益相關者視角
  • 法律和監管框架
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 其他地區
  • 產品對標

第4章 市場動態

  • 概述
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機會

第5章 競爭洞察

  • 概述
  • 主要戰略/發展
  • 市場佔有率分析
  • 成長佔有率分析

第6章 全球急性症候群檢測市場（按疾病類型）

  • 概述
  • 競爭分析
  • 呼吸系統疾病
    • 上呼吸道感染
    • 下呼吸道感染
  • 消化系統疾病
  • 泌尿生殖系統疾病
    • 尿路感染
    • 性病
  • 熱帶病
  • 其他

第7章 全球急性症候群檢測市場（按目標）

  • 概述
  • 細菌
    • 革蘭氏陽性菌
    • 革蘭氏陰性菌
  • 病毒
  • 菌類
  • 寄生蟲

第8章 全球急性症候群檢測市場（按樣本類型）

  • 概述
  • 血
  • 尿
  • 生物體液
    • 唾液
    • 痰
  • 糞便
  • 拭子
    • 生殖器拭子
    • 鼻咽拭子
  • 其他

第9章 全球急性症候群檢測市場（按最終用戶）

  • 概述
  • 醫院
  • 臨床/診斷實驗室
  • 研究和學術機構
  • 其他

第10章 全球急性症候群檢測市場（按地區）

  • 概述
  • 北美
  • 亞太地區
  • 歐洲
  • 拉丁美洲
  • 其他地區

第11章 公司簡介

  • Acute Care Syndromic Testing Ecosystem Active Players
  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Biocartis NV
  • bioMerieux SA（BioFire Diagnostics）
  • Danaher Corporation（Cepheid, Inc.）
  • DiaSorin SpA（Luminex Corporation）
  • Eurofins Scientific（Eurofins Viracor）
  • Karius
  • Laboratory Corporation of America Holdings.
  • QIAGEN NV
  • QuantuMDx Group Ltd.
  • Seegene Inc.
  • Siemens Healthineers AG
  • SpeeDx
  • Thermo Fisher Scientific Inc.
Product Code: BHP1393SA

“Global Acute Care Syndromic Testing Market to Reach $8.44 Billion by 2033.”

Introduction of Acute Care Syndromic Testing

The acute care syndromic testing market was valued at $3.14 billion in 2022 and is expected to reach $8.44 billion by 2033, growing at a CAGR of 9.43% between 2023 and 2033. Syndromic panels are molecular diagnostics tests that can detect more than one pathogen at the same time. These pathogens generally have similar or overlapping clinical symptomatology, which enables better management of patients and easier diagnosis with respect to certain symptoms.

KEY MARKET STATISTICS
Start Year2023
Forecast Year2033
Start Value$3.43 Billion in 2023
Forecast Value$3.43 Billion in 2023
CAGR %9.43%

Market Introduction

Before the advent of syndromic tests' physicians relied on the single-plex test, which could detect one pathogen at a time, and multiple tests had to be done to finally identify the pathogen causing the disease. Additionally, till all the tests were completed, physicians had to rely on general therapy until definitive results were available. This delayed the treatment process. As per BIS research, the acute care syndromic testing market includes panels and instruments that can test for more than one type of pathogen and specific instruments that are used to perform these tests. These are predominantly polymerase chain reaction-based testing kits, panels, or assays. The most common syndromic testing panels include respiratory, gastrointestinal, genitourinary, and tropical diseases, among others.

Industrial Impact

The global acute care syndromic testing market has witnessed significant growth, attributed to the increasing demand for early detection of infectious diseases. The increasing prevalence of infectious diseases and the increasing occurrence of pandemics have played a critical role in market growth. Furthermore, the rising temperature of the planet and the detection of new infectious disease in regions around the world is also influencing the market growth.

Global acute care syndromic testing has immense potential to deliver the next level of healthcare solutions. For instance, in April 2023, Abbott Laboratories partnered with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which is a group of more than 100 scientists globally in various academia and public health agencies. With this partnership, they plan to use diagnostic testing and data science technologies to mitigate future disease outbreaks. Additionally, the advent of better diagnosing, predicting, treating, and monitoring tools for infectious diseases is driving the acute care syndromic testing market growth. Other factors also impact the market growth, including increased patient demand and low turnaround time of these tests.

Market Segmentation:

Segmentation 1: by Disease Type

  • Respiratory Diseases
    • Upper Respiratory Tract Infections
    • Lower Respiratory Tract Infections
  • Gastrointestinal Diseases
  • Genitourinary Diseases
    • Urinary Tract Diseases
    • Sexually Transmitted Diseases
  • Tropical Diseases
  • Other Disease Types

Respiratory Diseases Segment to Dominate the Global Acute Care Syndromic Testing Market (by Disease Type)

The acute care syndromic testing market is led by the respiratory panels, with a 56.29% share in 2022. The burden of viral respiratory illnesses and pneumonia is huge, and thus syndromic diagnostic testing is a good and fast approach to distinguish between viral and bacterial respiratory pathogens and should be implemented by hospitals and doctors aiming to optimize antimicrobial use.

Segmentation 2: by Target

  • Bacteria
  • Viruses
  • Fungi
  • Parasites

Bacteria Segment to Dominate the Global Acute Care Syndromic Testing Market (by Target)

The acute care syndromic testing market is led by bacteria panels, with a 41.65% share in 2022. Bacteria are microbes that have a simple cell structure with a control center that contains genetic information, and the DNA is contained in a single loop. Bacterial can cause numerous types of infections that can affect humans as well as animals. These infections can affect the skin, brain, lungs, blood, or any other body part of the human body. The infection increases as the bacteria multiply and that increase the area of infection.

Segmentation 3: by Sample Type

  • Blood
  • Urine
  • Biofluids
  • Stool
  • Swabs
  • Others

Swabs Segment to Dominate the Global Acute Care Syndromic Testing Market (by Sample Type)

The acute care syndromic testing market is led by swabs, with a 51.90% share in 2022. The key reason for the increasing popularity of swabs is that it is an easy-to-use, non-invasive, and inexpensive sampling method.

Segmentation 4: by End User

  • Hospitals
  • Clinical and Diagnostic Laboratories
  • Research and Academic Institutions
  • Other End Users

Hospitals Segment to Dominate the Global Acute Care Syndromic Testing Market (by End User)

The acute care syndromic testing market is led by hospitals, with a 42.53% share in 2022. Hospitals are also at the forefront of adopting syndromic testing panels into routine healthcare procedures. Hospitals, particularly in leading regions such as North America and Europe, and also to a certain extent in Asia-Pacific, have incorporated syndromic testing panels and assays to provide superior care to patients.

Segmentation 5: by Region

  • North America - U.S., Canada
  • Europe - Germany, U.K., France, Italy, Spain, and Rest-of-Europe
  • Asia-Pacific - Japan, India, China, South Korea, Australia, and Rest-of-Asia-Pacific
  • Latin America - Brazil, Mexico, and Rest-of-Latin America
  • Rest-of-the-World

North America held the highest market share at 40.41% in 2022, mainly due to the high number of legacy companies in the region. Further, increasing approvals and synergistic activities are also increasing their dominance in the market. However, the highest CAGR in the market was seen by Asia-Pacific at 10.97% due to the increasing adoption of syndromic panels in the region, especially in highly populated countries such as China and India.

Recent Developments in the Acute Care Syndromic Testing Market

  • In May 2023, Hologic, Inc. got FDA clearance for its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. This molecular diagnostic test can test for the most prevalent respiratory viruses exhibiting similar conditions all at once, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), influenza A (flu A), influenza B (flu B), and respiratory syncytial virus (RSV).
  • In March 2023, Lucira Health got FDA approval for its home testing kit that can detect respiratory infections, including COVID-19 and flu. It is easy to use at-home test and can be done on children as young as two years old.
  • In April 2023, Abbott Laboratories partnered with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which is a group of more than 100 scientists globally in various academia and public health agencies. With this partnership, they plan to use diagnostic testing and data science technologies to mitigate future disease outbreaks.
  • In May 2023, Applied BioCode, Inc. made an agreement with Medline Industries, which is an industry leader in distributing healthcare products. Medline Industries agreed to distribute the MDx-3000 system, which enables the diagnosis of gastrointestinal and upper respiratory infections, in addition to a suite of Analyte Specific Reagents (ASRs).
  • In April 2023, QIAGEN N.V. announced the availability of its QIAstat-Dx syndromic testing solution in Japan, which can detect more than 20 respiratory pathogens, including SARS-CoV-2, from a single sample.
  • In January 2023, Fusion Genomics established a fully automated, first-of-its-kind facility for infectious disease surveillance at the Toronto Pearson Internation Airport. This facility is using the company's ONETest platform for the detection of SARS-CoV-2 and other respiratory pathogens in wastewater.

Demand - Drivers, Challenges, and Opportunities

Market Demand Drivers:

  • Faster Results Acquired with Syndromic Tests: The traditional single-plex testing methods for infectious disease detection use methods such as microscopy and bacterial culture, whereas syndromic multi-plex tests use PCRs. This is where syndromic testing really shines, as PCR testing is more accurate and less time-consuming. These quick and comprehensive results then allow physicians to provide better care for the patients and make faster clinical decisions.
  • Increasing Incidence of Infectious Diseases: The global health system is undergoing severe change as the incidence of infectious diseases constantly increases and building a system against known and unknown pathogen threats. Governments from all over the world have joined hands to maintain the risk of the pandemic at all levels, including the different regional levels such as local, national, and regional. Even though this global health system is doing a lot to protect and promote human health, the world is always being confronted by numerous emerging, reemerging, and longstanding infectious diseases.
  • Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing: Diagnosis of infectious diseases can be made much easier with the help of syndromic testing. This benefits not only the individual patient but the institution as a whole in numerous ways, especially by decreasing the costs for patients drastically. If the correct pathogen is not detected on the first try using singleplex testing, then subsequent tests are just an added cost which also takes patients time till the final diagnosis. Higher treatment costs due to later diagnosis and, thus, more aggressive treatment measures are big issues that can be addressed with the use of syndromic panels and decrease the personal and economic burden on the individual and their family/friends.

Market Challenges:

  • The Need for Better Reimbursement of Syndromic Tests: Syndromic panels have faster turnaround time and can save patients money in the long run. However, there is still a gap in the reimbursement of these panels. This is because not all syndromic panels are FDA-approved and thus are not reimbursed. Additionally, all home-use panels, including the ones approved by the FDA, are not reimbursed. This slows down the adoption of these syndromic panels, which can only increase to all income classes if either these panels are constantly reimbursed, or the cost of syndromic panels drastically decreases.
  • Lack of High-Complexity Testing Center: With the ongoing rapid advancements, new genomic platforms require significant capital investment and high-test volume to enable operation at scale and achieve competitive price points. Additionally, there is also difficulty in establishing and maintaining different technology platforms.

Market Opportunities:

  • Quick Access to Treatment and Reduced Use of Antibiotics: When diagnosed with an infectious disease, the most efficient cure for late-stage infections is antibiotics. This can be combated with the use of syndromic testing, as it can help to detect pathogens at the earliest stages. According to a report by Zhu et al. published in 2019, stated that antibiotic prescriptions could be reduced by 30% with the use of syndromic testing.
  • High Number of Synergic Activities and Mergers and Acquisitions: The acute care syndromic testing market has witnessed many synergistic activities and mergers and acquisitions since January 2020. This is leading to the consolidation of the market. In June 2022, R-Biopharm acquired AusDiagnostics and with it their wide range of syndromic diseases testing product range.

How Can This Report Add Value to an Organization?

  • Product/Innovation Strategy: The global acute care syndromic testing market has been extensively segmented on the basis of various categories, such as disease type, target, sample type, end user, and region. This can help readers get a clear overview of which segments account for the largest share and which ones are well-positioned to grow in the coming years.
  • Growth/Marketing Strategy: Synergistic activities, product launches, and approvals accounted for the maximum number of key developments, i.e., nearly 91% of the total developments in the global acute care syndromic testing market were between January 2021 to June 2023.
  • Competitive Strategy: The global acute care syndromic testing market has numerous startups paving their way into manufacturing kits, panels, assays, and instruments and entering the market. Key players in the global acute care syndromic testing market analyzed and profiled in the study involve established players that offer various kinds of disease-specific panels and multiplex instruments.

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

The top disease-type segment players who are leading capture around 56.30% of the presence in the market. Players in other industries, such as gastrointestinal, genitourinary, and tropical disease, among others, account for approximately 43.70% of the presence in the market.

Key Companies Profiled:

  • Abbott Laboratories
  • Becton, Dickinson and Company
  • Biocartis NV
  • bioMerieux SA (BioFire Diagnostics)
  • Danaher Corporation (Cepheid, Inc.)
  • DiaSorin S.p.A (Luminex Corporation)
  • Eurofins Scientific (Eurofins Viracor)
  • Karius
  • Laboratory Corporation of America Holdings.
  • QIAGEN N.V.
  • QuantuMDx Group Ltd.
  • Seegene Inc.
  • Siemens Healthineers AG
  • SpeeDx
  • Thermo Fisher Scientific Inc.

Table of Contents

1 Markets

  • 1.1 Product Definition
  • 1.2 Inclusion and Exclusion Criteria
  • 1.3 Market Scope
    • 1.3.1 Scope of the Study
    • 1.3.2 Key Questions Answered in the Report
  • 1.4 Research Methodology
    • 1.4.1 Global Acute Care Syndromic Testing Market: Research Methodology
    • 1.4.2 Data Sources
      • 1.4.2.1 Primary Data Sources
      • 1.4.2.2 Secondary Data Sources
    • 1.4.3 Market Estimation Model
    • 1.4.4 Criteria for Company Profiling

2 Market Overview

  • 2.1 Overview
  • 2.2 Acute Care Syndromic Testing Workflow Analysis
  • 2.3 Market Footprint and Growth Potential
  • 2.4 Future Potential

3 Industry Insight

  • 3.1 Stakeholder's Perspective (N=20)
    • 3.1.1 Physician's Perception
    • 3.1.2 Payor's Perception
    • 3.1.3 Investor's Perception
  • 3.2 Legal and Regulatory Framework of the Global Acute Care Syndromic Testing Market
    • 3.2.1 Regulatory Framework in North America
      • 3.2.1.1 The U.S.
      • 3.2.1.2 Canada
    • 3.2.2 Regulatory Framework in Europe
    • 3.2.3 Regulatory Framework in Asia-Pacific
      • 3.2.3.1 Japan
      • 3.2.3.2 China
      • 3.2.3.3 India
      • 3.2.3.4 South Korea
      • 3.2.3.5 Australia
    • 3.2.4 Regulatory Framework in Latin America
      • 3.2.4.1 Brazil
      • 3.2.4.2 Mexico
    • 3.2.5 Regulatory Framework in Rest-of-the-World
      • 3.2.5.1 U.A.E.
      • 3.2.5.2 K.S.A.
  • 3.3 Product Benchmarking

4 Market Dynamics

  • 4.1 Overview
  • 4.2 Impact Analysis
  • 4.3 Market Drivers
    • 4.3.1 Faster Results Acquired with Syndromic Tests
    • 4.3.2 Increasing Incidence of Infectious Diseases
    • 4.3.3 Overall Reduced Cost of Care Due to Early Diagnosis with Syndromic Testing
    • 4.3.4 Reduced Severe Adverse Effects from Pathogens
  • 4.4 Market Challenges
    • 4.4.1 Need for Better Policies with Respect to Acute Care Syndromic Test Reimbursement
    • 4.4.2 Lack of High-Complexity Testing Centres
  • 4.5 Market Opportunities
    • 4.5.1 Quick Access to Treatment and Reduced Use of Antibiotics
    • 4.5.2 High Number of Synergistic Activities and Mergers and Acquisitions (M&A) Over the Past Years

5 Competitive Insight

  • 5.1 Overview
  • 5.2 Key Strategies and Developments
    • 5.2.1 Synergistic Activities
    • 5.2.2 Product Launches and Product Approvals
    • 5.2.3 Funding and Expansion
    • 5.2.4 Mergers and Acquisitions
  • 5.3 Market Share Analysis (2022)
  • 5.4 Growth-Share Analysis (2022)
    • 5.4.1 Growth-Share Analysis (by Disease Type)
    • 5.4.2 Growth-Share Analysis (by Target)

6 Global Acute Care Syndromic Testing Market (By Disease Type), 2022-2033

  • 6.1 Overview
  • 6.2 Competitive Analysis
  • 6.3 Respiratory Diseases
    • 6.3.1 Upper Respiratory Tract Infections
    • 6.3.2 Lower Respiratory Tract Infections
  • 6.4 Gastrointestinal Diseases
  • 6.5 Genitourinary Diseases
    • 6.5.1 Urinary Tract Infections
    • 6.5.2 Sexually Transmitted Diseases
  • 6.6 Tropical Diseases
  • 6.7 Others

7 Global Acute Care Syndromic Testing Market (By Target), 2022-2033

  • 7.1 Overview
  • 7.2 Bacteria
    • 7.2.1 Gram-Positive Bacteria
    • 7.2.2 Gram-Negative Bacteria
  • 7.3 Viruses
  • 7.4 Fungi
  • 7.5 Parasites

8 Global Acute Care Syndromic Testing Market (By Sample Type), 2022-2033

  • 8.1 Overview
  • 8.2 Blood
  • 8.3 Urine
  • 8.4 Biofluids
    • 8.4.1 Saliva
    • 8.4.2 Sputum
  • 8.5 Stool
  • 8.6 Swabs
    • 8.6.1 Genital Swabs
    • 8.6.2 Nasopharyngeal Swabs
  • 8.7 Other Sample Types

9 Global Acute Care Syndromic Testing Market (By End User), 2022-2033

  • 9.1 Overview
  • 9.2 Hospitals
  • 9.3 Clinical and Diagnostic Laboratories
  • 9.4 Research and Academic Institutions
  • 9.5 Other End Users

10 Global Acute Care Syndromic Testing Market (By Region), 2022-2033

  • 10.1 Overview
  • 10.2 North America
    • 10.2.1 North America Acute Care Syndromic Testing Market, By End User
    • 10.2.2 North America Acute Care Syndromic Testing Market, By Country
      • 10.2.2.1 U.S.
      • 10.2.2.2 Canada
  • 10.3 Asia-Pacific
    • 10.3.1 Asia-Pacific Acute Care Syndromic Testing Market, By End User
    • 10.3.2 Asia-Pacific Acute Care Syndromic Testing Market, By Country
      • 10.3.2.1 China
      • 10.3.2.2 Japan
      • 10.3.2.3 India
      • 10.3.2.4 Australia
      • 10.3.2.5 South Korea
      • 10.3.2.6 Rest-of-Asia-Pacific
  • 10.4 Europe
    • 10.4.1 Europe Acute Care Syndromic Testing Market, By End User
    • 10.4.2 Europe Acute Care Syndromic Testing Market, By Country
      • 10.4.2.1 Germany
      • 10.4.2.2 France
      • 10.4.2.3 U.K.
      • 10.4.2.4 Italy
      • 10.4.2.5 Spain
      • 10.4.2.6 Rest-of-Europe
  • 10.5 Latin America
    • 10.5.1 Latin America Acute Care Syndromic Testing Market, By End User
    • 10.5.2 Latin America Acute Care Syndromic Testing Market, By Country
      • 10.5.2.1 Brazil
      • 10.5.2.2 Mexico
      • 10.5.2.3 Rest-of-Latin America
  • 10.6 Rest-of-the-World
    • 10.6.1 Rest-of-the-World Acute Care Syndromic Testing Market, By End User

11 Company Profiles

  • 11.1 Overview
  • 11.2 Acute Care Syndromic Testing Ecosystem Active Players
  • 11.3 Abbott Laboratories
    • 11.3.1 Company Overview
    • 11.3.2 Role of Abbott Laboratories in the Global Acute Care Syndromic Testing Market
    • 11.3.3 Financials
    • 11.3.4 Recent Developments
      • 11.3.4.1 Corporate Strategies
      • 11.3.4.2 Business Strategies
    • 11.3.5 Analyst Perspective
  • 11.4 Becton, Dickinson and Company
    • 11.4.1 Company Overview
    • 11.4.2 Role of Becton, Dickinson and Company in the Global Acute Care Syndromic Testing Market
    • 11.4.3 Financials
    • 11.4.4 Recent Developments
      • 11.4.4.1 Corporate Strategies
      • 11.4.4.2 Business Strategies
    • 11.4.5 Analyst Perspective
  • 11.5 Biocartis NV
    • 11.5.1 Company Overview
    • 11.5.2 Role of Biocartis NV in the Global Acute Care Syndromic Testing Market
    • 11.5.3 Financials
    • 11.5.4 Recent Developments
      • 11.5.4.1 Business Strategies
    • 11.5.5 Analyst Perspective
  • 11.6 bioMerieux SA (BioFire Diagnostics)
    • 11.6.1 Company Overview
    • 11.6.2 Role of bioMerieux SA (BioFire Diagnostics) in the Global Acute Care Syndromic Testing Market
    • 11.6.3 Financials
    • 11.6.4 Recent Developments
      • 11.6.4.1 Business Strategies
    • 11.6.5 Analyst Perspective
  • 11.7 Danaher Corporation (Cepheid, Inc.)
    • 11.7.1 Company Overview
    • 11.7.2 Role of Danaher Corporation (Cepheid, Inc.) in the Global Acute Care Syndromic Testing Market
    • 11.7.3 Financials
    • 11.7.4 Recent Developments
      • 11.7.4.1 Corporate Strategies
      • 11.7.4.2 Business Strategies
    • 11.7.5 Analyst Perspective
  • 11.8 DiaSorin S.p.A (Luminex Corporation)
    • 11.8.1 Company Overview
    • 11.8.2 Role of DiaSorin S.p.A (Luminex Corporation) in the Global Acute Care Syndromic Testing Market
    • 11.8.3 Financials
    • 11.8.4 Recent Developments
      • 11.8.4.1 Corporate Strategies
      • 11.8.4.2 Business Strategies
    • 11.8.5 Analyst Perspective
  • 11.9 Eurofins Scientific (Eurofins Viracor)
    • 11.9.1 Company Overview
    • 11.9.2 Role of Eurofins Scientific (Eurofins Viracor) in the Global Acute Care Syndromic Testing Market
    • 11.9.3 Financials
    • 11.9.4 Recent Developments
      • 11.9.4.1 Business Strategies
    • 11.9.5 Analyst Perspective
  • 11.1 Karius
    • 11.10.1 Company Overview
    • 11.10.2 Role of Karius in the Global Acute Care Syndromic Testing Market
    • 11.10.3 Recent Developments
      • 11.10.3.1 Business Strategies
    • 11.10.4 Analyst Perspective
  • 11.11 Laboratory Corporation of America Holdings.
    • 11.11.1 Company Overview
    • 11.11.2 Role of Laboratory Corporation of America Holdings. in the Global Acute Care Syndromic Testing Market
    • 11.11.3 Financials
    • 11.11.4 Analyst Perspective
  • 11.12 QIAGEN N.V.
    • 11.12.1 Company Overview
    • 11.12.2 Role of QIAGEN N.V. in the Global Acute Care Syndromic Testing Market
    • 11.12.3 Financials
    • 11.12.4 Recent Developments
      • 11.12.4.1 Business Strategies
    • 11.12.5 Analyst Perspective
  • 11.13 QuantuMDx Group Ltd.
    • 11.13.1 Company Overview
    • 11.13.2 Role of QuantuMDx Group Ltd. in the Global Acute Care Syndromic Testing Market
    • 11.13.3 Recent Developments
      • 11.13.3.1 Corporate Strategies
      • 11.13.3.2 Business Strategies
    • 11.13.4 Analyst Perspective
  • 11.14 Seegene Inc.
    • 11.14.1 Company Overview
    • 11.14.2 Role of Seegene, Inc. in the Global Acute Care Syndromic Testing Market
    • 11.14.3 Financials
    • 11.14.4 Recent Developments
      • 11.14.4.1 Corporate Strategies
      • 11.14.4.2 Business Strategies
    • 11.14.5 Analyst Perspective
  • 11.15 Siemens Healthineers AG
    • 11.15.1 Company Overview
    • 11.15.2 Role of Siemens Healthineers AG in the Global Acute Care Syndromic Testing Market
    • 11.15.3 Financials
    • 11.15.4 Analyst Perspective
  • 11.16 SpeeDx
    • 11.16.1 Company Overview
    • 11.16.2 Role of SpeeDX in the Global Acute Care Syndromic Testing Market
    • 11.16.3 Analyst Perspective
  • 11.17 Thermo Fisher Scientific Inc.
    • 11.17.1 Company Overview
    • 11.17.2 Role of Thermo Fisher Scientific Inc. in the Global Acute Care Syndromic Testing Market
    • 11.17.3 Financials
    • 11.17.4 Recent Developments
      • 11.17.4.1 Business Strategies
    • 11.17.5 Analyst Perspective

List of Figures

  • Figure 1: Global Acute Care Syndromic Testing Market, $Billion, 2023 and 2033
  • Figure 2: History of Known Pandemics
  • Figure 3: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
  • Figure 4: Global Acute Care Syndromic Testing Market (by Disease Type), Share (%), 2022 and 2033
  • Figure 5: Global Acute Care Syndromic Testing Market (by Target), Share (%), 2022 and 2033
  • Figure 6: Share of Global Acute Care Syndromic Testing Market (by Region), 2022
  • Figure 7: Share of Key Developments and Strategies, January 2020-June 2023
  • Figure 8: Global Acute Care Syndromic Testing Market (by Company), Share (%), 2022
  • Figure 9: Global Acute Care Syndromic Testing Market Segmentation
  • Figure 10: Global Acute Care Syndromic Testing Market: Research Methodology
  • Figure 11: Primary Research Methodology
  • Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 13: Top-Down Approach (Segment-Wise Analysis)
  • Figure 14: Acute Care Syndromic Testing Workflow
  • Figure 15: Global Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 16: Physician's Perception on the Factors Affecting the Adoption of Acute Care Syndromic Testing
  • Figure 17: Global Acute Care Syndromic Testing Market Dynamics
  • Figure 18: Traditional Testing vs. Syndromic Testing
  • Figure 19: Incidence of Common Infectious Diseases in the U.S (Excluding Influenza), 2020
  • Figure 20: Incidence of Common Infectious Diseases in Germany (Excluding COVID-19), 2020
  • Figure 21: Incidence of Common Infectious Diseases in China, 2020
  • Figure 22: History of Known Pandemics
  • Figure 23: Examples of Cost Reductions
  • Figure 24: Time of Diagnosis vs. Disease Effect
  • Figure 25: Syndromic Panels Reimbursement Scenario in the U.S.
  • Figure 26: Syndromic Panels Reimbursement Scenario in Mexico
  • Figure 27: Reduction in Antibiotics Use with Syndromic Testing
  • Figure 28: Increasing Synergistic Activities of the Global Acute Care Syndromic Testing Market, January 2021-June 2023 (Number of Partnerships, Collaborations and Agreements)
  • Figure 29: Key Mergers and Acquisitions in the Global Acute Care Syndromic Testing Market
  • Figure 30: Share of Key Developments and Strategies, January 2020-June 2023
  • Figure 31: Share of Synergistic Activities (by Company), January 2020-June 2023
  • Figure 32: Number of Product Launches and Product Approvals (by Company), January 2020-June 2023
  • Figure 33: Number of Mergers and Acquisitions (by Company), January 2020-June 2023
  • Figure 34: Global Acute Care Syndromic Testing Market (by Company), Share (%), 2022
  • Figure 35: Global Acute Care Syndromic Testing Market, Growth-Share Matrix (by Disease Type), 2023-2033
  • Figure 36: Global Acute Care Syndromic Testing Market, Growth-Share Matrix (by Target), 2023-2033
  • Figure 37: Global Acute Care Syndromic Testing Market (by Disease Type)
  • Figure 38: Global Acute Care Syndromic Testing Market (by Disease Type), Share (%), 2022 and 2033
  • Figure 39: Global Acute Care Syndromic Testing Market (Respiratory Diseases), $Billion, 2022-2033
  • Figure 40: Global Acute Care Syndromic Testing Market (Upper Respiratory Tract Infections), $Billion, 2022-2033
  • Figure 41: Global Acute Care Syndromic Testing Market (Lower Respiratory Tract Infections), $Billion, 2022-2033
  • Figure 42: Global Acute Care Syndromic Testing Market (Gastrointestinal Diseases), $Billion, 2022-2033
  • Figure 43: Global Acute Care Syndromic Testing Market (Genitourinary Diseases), $Billion, 2022-2033
  • Figure 44: Global Acute Care Syndromic Testing Market (Urinary Tract Infections), $Billion, 2022-2033
  • Figure 45: Global Acute Care Syndromic Testing Market (Sexually Transmitted Diseases), $Billion, 2022-2033
  • Figure 46: Global Acute Care Syndromic Testing Market (Tropical Diseases), $Billion, 2022-2033
  • Figure 47: Global Acute Care Syndromic Testing Market (Others), $Billion, 2022-2033
  • Figure 48: Global Acute Care Syndromic Testing Market (by Target)
  • Figure 49: Global Acute Care Syndromic Testing Market (by Target), Share (%), 2022 and 2033
  • Figure 50: Global Acute Care Syndromic Testing Market (Bacteria), $Billion, 2022-2033
  • Figure 51: Global Acute Care Syndromic Testing Market (Gram-Positive Bacteria), $Billion, 2022-2033
  • Figure 52: Global Acute Care Syndromic Testing Market (Gram-Negative Bacteria), $Billion, 2022-2033
  • Figure 53: Global Acute Care Syndromic Testing Market (Viruses), $Billion, 2022-2033
  • Figure 54: Global Acute Care Syndromic Testing Market (Fungi), $Billion, 2022-2033
  • Figure 55: Global Acute Care Syndromic Testing Market (Parasites), $Billion, 2022-2033
  • Figure 56: Global Acute Care Syndromic Testing Market (by Sample Type)
  • Figure 57: Global Acute Care Syndromic Testing Market (by Sample Type), Share (%), 2022 and 2033
  • Figure 58: Global Acute Care Syndromic Testing Market (Blood), $Billion, 2022-2033
  • Figure 59: Global Acute Care Syndromic Testing Market (Urine), $Billion, 2022-2033
  • Figure 60: Global Acute Care Syndromic Testing Market (Biofluids), $Billion, 2022-2033
  • Figure 61: Global Acute Care Syndromic Testing Market (Saliva), $Billion, 2022-2033
  • Figure 62: Global Acute Care Syndromic Testing Market (Sputum), $Billion, 2022-2033
  • Figure 63: Global Acute Care Syndromic Testing Market (Stool), $Billion, 2022-2033
  • Figure 64: Global Acute Care Syndromic Testing Market (Swabs), $Billion, 2022-2033
  • Figure 65: Global Acute Care Syndromic Testing Market (Genital Swab), $Billion, 2022-2033
  • Figure 66: Global Acute Care Syndromic Testing Market (Nasopharyngeal Swabs), $Billion, 2022-2033
  • Figure 67: Global Acute Care Syndromic Testing Market (Other Sample Types), $Billion, 2022-2033
  • Figure 68: Global Acute Care Syndromic Testing Market (by End User)
  • Figure 69: Global Acute Care Syndromic Testing Market (by End User), Share (%), 2022 and 2033
  • Figure 70: Global Acute Care Syndromic Testing Market (Hospitals), $Billion, 2022-2033
  • Figure 71: Global Acute Care Syndromic Testing Market (Clinical and Diagnostic Laboratories), $Billion, 2022-2033
  • Figure 72: Global Acute Care Syndromic Testing Market (Research and Academic Institutions), $Billion, 2022-2033
  • Figure 73: Global Acute Care Syndromic Testing Market (Other End Users), $Billion, 2022-2033
  • Figure 74: Global Acute Care Syndromic Testing Market Snapshot (by Region)
  • Figure 75: Global Acute Care Syndromic Testing Market (by Region), $Billion, 2022-2033
  • Figure 76: North America Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 77: North America Acute Care Syndromic Testing Market (by End User), $Billion, 2023-2033
  • Figure 78: North America Acute Care Syndromic Testing Market (by Country), $Billion, 2022-2033
  • Figure 79: Top Five Infectious Diseases in the U.S., 2019
  • Figure 80: U.S. Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 81: Canada Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 82: Asia-Pacific Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 83: Asia-Pacific Acute Care Syndromic Testing Market (by End User), $Billion, 2022-2033
  • Figure 84: Asia-Pacific Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
  • Figure 85: Reported Cases of Top 5 Infectious Diseases, China, 2020
  • Figure 86: China Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 87: Japan Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 88: India Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 89: Incidence of the Most Common Infectious Diseases in Australia, 2021
  • Figure 90: Australia Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 91: South Korea Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 92: Rest-of-Asia-Pacific Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 93: Europe Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 94: Europe Acute Care Syndromic Testing Market (by End User), $Billion, 2023-2033
  • Figure 95: Europe Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
  • Figure 96: Top 5 Most Common Infectious Diseases in Germany, 2020
  • Figure 97: Germany Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 98: France Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 99: U.K. Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 100: Italy Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 101: Spain Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 102: Rest-of-Europe Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 103: Latin America Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 104: Latin America Acute Care Syndromic Testing Market (by End User), $Million, 2022-2033
  • Figure 105: Latin America Acute Care Syndromic Testing Market (by Country), $Million, 2022-2033
  • Figure 106: Brazil Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 107: Mexico Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 108: Rest-of-Latin America Acute Care Syndromic Testing Market, $Million, 2022-2033
  • Figure 109: Rest-of-the-World Acute Care Syndromic Testing Market, $Billion, 2022-2033
  • Figure 110: Rest-of-the-World Acute Care Syndromic Testing Market (by End User), $Million, 2023-2033
  • Figure 111: Global Acute Care Syndromic Testing Market, Total Number of Companies Profiled
  • Figure 112: Abbott Laboratories: Product Portfolio
  • Figure 113: Abbott Laboratories: Overall Financials, $Million, 2020-2022
  • Figure 114: Abbott Laboratories: Revenue (by Segment), $Million, 2020-2022
  • Figure 115: Abbott Laboratories: Revenue (by Region), $Million, 2020-2022
  • Figure 116: Abbott Laboratories: R&D Expenditure, $Million, 2020-2022
  • Figure 117: Becton, Dickinson and Company: Product Portfolio
  • Figure 118: Becton, Dickinson and Company: Overall Financials, $Million, 2020-2022
  • Figure 119: Becton, Dickinson and Company: Revenue (by Segment), $Million, 2020-2022
  • Figure 120: Becton, Dickinson and Company: Revenue (by Region), $Million, 2020-2022
  • Figure 121: Becton, Dickinson and Company: R&D Expenditure, $Million, 2020-2022
  • Figure 122: Biocartis NV: Product Portfolio
  • Figure 123: Biocartis NV: Overall Financials, $Million, 2020-2022
  • Figure 124: Biocartis NV: R&D Expenditure, $Million, 2020-2022
  • Figure 125: bioMerieux SA (BioFire Diagnostics): Product Portfolio
  • Figure 126: bioMerieux SA (BioFire Diagnostics): Overall Financials, $Million, 2020-2022
  • Figure 127: bioMerieux SA (BioFire Diagnostics): Revenue (by Segment), $Million, 2020-2022
  • Figure 128: bioMerieux SA (BioFire Diagnostics): Revenue (by Region), $Million, 2020-2022
  • Figure 129: bioMerieux SA (BioFire Diagnostics): R&D Expenditure, $Million, 2020-2022
  • Figure 130: Danaher Corporation (Cepheid, Inc.): Product Portfolio
  • Figure 131: Danaher Corporation (Cepheid, Inc.): Overall Financials, $Million, 2020-2022
  • Figure 132: Danaher Corporation (Cepheid, Inc.): Revenue (by Segment), $Million, 2020-2022
  • Figure 133: Danaher Corporation (Cepheid, Inc.): Revenue (by Region), $Million, 2020-2022
  • Figure 134: Danaher Corporation (Cepheid, Inc.): R&D Expenditure, $Million, 2020-2022
  • Figure 135: DiaSorin S.p.A (Luminex Corporation): Product Portfolio
  • Figure 136: DiaSorin S.p.A (Luminex Corporation): Overall Financials, $Million, 2021 and 2022
  • Figure 137: DiaSorin S.p.A (Luminex Corporation): Revenue (by Region), $Million, 2021 and 2022
  • Figure 138: DiaSorin S.p.A (Luminex Corporation): R&D Expenditure, $Million, 2021 and 2022
  • Figure 139: Eurofins Scientific (Eurofins Viracor): Product Portfolio
  • Figure 140: Eurofins Scientific (Eurofins Viracor): Overall Financials, $Million, 2020-2022
  • Figure 141: Eurofins Scientific (Eurofins Viracor): Revenue (by Segment), $Million, 2020-2022
  • Figure 142: Eurofins Scientific (Eurofins Viracor): Revenue (by Region), $Million, 2020-2022
  • Figure 143: Karius: Product Portfolio
  • Figure 144: Laboratory Corporation of America Holdings.: Product Portfolio
  • Figure 145: Laboratory Corporation of America Holdings.: Overall Financials, $Million, 2020-2022
  • Figure 146: Laboratory Corporation of America Holdings.: Revenue (by Segment), $Million, 2020-2022
  • Figure 147: Laboratory Corporation of America Holdings.: Revenue (by Region), $Million, 2020-2022
  • Figure 148: QIAGEN N.V.: Product Portfolio
  • Figure 149: QIAGEN N.V.: Overall Financials, $Million, 2020-2022
  • Figure 150: QIAGEN N.V.: Revenue (by Segment), $Million, 2020-2022
  • Figure 151: QIAGEN N.V.: Revenue (by Region), $Million, 2020-2022
  • Figure 152: QIAGEN N.V.: R&D Expenditure, $Million, 2020-2022
  • Figure 153: QuantuMDx Group Ltd.: Product Portfolio
  • Figure 154: Seegene, Inc.: Product Portfolio
  • Figure 155: Seegene, Inc.: Overall Financials, $Million, 2020-2022
  • Figure 156: Seegene, Inc.: Revenue (by Segment), $Million, 2020-2022
  • Figure 157: Seegene, Inc.: Revenue (by Region), $Million, 2020-2022
  • Figure 158: Seegene, Inc.: R&D Expenditure, $Million, 2020-2022
  • Figure 159: Siemens Healthineers AG: Product Portfolio
  • Figure 160: Siemens Healthineers AG: Overall Financials, $Million, 2020-2022
  • Figure 161: Siemens Healthineers AG: Revenue (by Segment), $Million, 2020-2022
  • Figure 162: Siemens Healthineers AG: Revenue (by Region), $Million, 2020-2022
  • Figure 163: Siemens Healthineers AG: R&D Expenditure, $Million, 2020-2022
  • Figure 164: SpeeDX: Product Portfolio
  • Figure 165: Thermo Fisher Scientific Inc.: Product Portfolio
  • Figure 166: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2020-2022
  • Figure 167: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2020-2022
  • Figure 168: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2020-2022
  • Figure 169: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
  • Table 2: Global Acute Care Syndromic Testing Market: Impact Analysis
  • Table 3: Key Questions Answered in the Report
  • Table 4: Product Benchmarking of Acute Care Syndromic Testing Panels
  • Table 5: Likert Scale
  • Table 6: Impact Analysis of Market Drivers
  • Table 7: Impact Analysis of Market Challenges
  • Table 8: Popular Assays and Their Turnaround Times
  • Table 9: Acute Care Syndromic Testing Product Mapping Analysis (by Disease Type)
  • Table 10: List of FDA-Cleared Upper Respiratory Tract Syndromic Panels
  • Table 11: Common Upper Tract Respiratory Infections Panels and Key Pathogens being Tested
  • Table 12: List of FDA-Cleared Lower Respiratory Tract Syndromic Panels
  • Table 13: Common Gastrointestinal Diseases Panels and Key Pathogens being Tested
  • Table 14: Common Genitourinary Diseases Panels and Key Pathogens being Tested
  • Table 15: Common Other Diseases Panels and Key Pathogens being Tested
  • Table 16: Global Acute Care Syndromic Testing Ecosystem Active Players